Open AccessThe effectiveness of piribedil for the treatment of cognitive disorders in patients with coronary heart disease: results of six-month
observation
Author(s) -
М. М. Петрова,
С. В. Прокопенко,
О. В. Еремина,
E. Yu. Mozhejko,
D. S. Kaskaeva,
М. И. Ганкин,
О. И. Шевченко
Publication year - 2017
Publication title -
kliničeskaâ medicina
Language(s) - English
Resource type - Journals
eISSN - 2412-1339
pISSN - 0023-2149
DOI - 10.18821/0023-2149-2017-95-5-445-450
Subject(s) - medicine , psychomotor learning , cognition , disease , coronary heart disease , anesthesia , surgery , psychiatry
Aim. The detection of cognitive deficiency after heart bypass surgery, the evaluation of the influence of piribedil on the higher cerebral function in the early postoperative period during the follow-up. Materials and methods. 64 patients with ischemic heart disease were examined. They were divided into two groups. Patients of the main group (n=32) were treated with pronoran (piribedil) at a daily dose of 50 mg for 3 months. 32 patients of the control group received standard therapy in the postoperative period. All patients had undergone heart bypass surgery. Cognitive functions were examined before operation, 10 days , three and six months after surgery. Results. Positive dynamics of all tested parameters was documented in the patients of the main group within 6 months after the onset of therapy. In control patients, cognitive disorders remained at the preoperative level based on the results of three tests. Conclusion. The positive results of piribedil therapy suggest that piribedil has positive effect on memory, attention and psychomotor activity of the patients